In the present study, we further showed that R-107 treatment improved bacterial clearance in the lung and kidney, inhibited increases in inflammatory mediators (plasma shed Sdc1, IL-6, and lung VEGF-A levels), delayed the onset of sepsis (measured by the qSOFA score), attenuated multi-organ dysfunction (measured by the mSOFA score), and improved multi-organ function. The gene discussed is SDC1; the disease is Sepsis.